Common Stock, $0.0001 par value per share
- Symbol
- VOGX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Vogenx Inc
VOGXNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 6, 2026, Vogenx, Inc. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.…
Company context
We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. Our company was founded in 2021 by experienced leaders with proven expertise developing drugs in the metabolic disease space. Our primary objective is to advance our lead investigational product candidate, mizagliflozin, a selective inhibitor of the sodium-glucose transporter 1, or SGLT1, through clinical development for disorders related to glucose absorption and postprandial dysregulation, and towards regulatory approval.
Current securities
Registered securities in this filing
VOGENX, INC. · 8-K · Filed 2026-11-06
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition.
On November 6, 2026, Vogenx, Inc. issued a
press release announcing its financial results for the fiscal quarter ended September 30, 2026. A copy of the press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in this Current Report on Form 8-K, including
Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it
be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall
be expressly set forth by specific reference in such a filing.
Filed exhibits (1)
Exhibit 99.1 Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights Advances PBH Development Program Following August 2026 Initial Public Offering Strengthens Balance Sheet with $82.1 Million in Total Cash, Cash Equivalents, and Marketable Securities RALEIGH, NC / ACCESS Newswire / November 6, 2026 - Vogenx, Inc. (Nasdaq: VOGX), a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced its financial results for the third quarter and provided a corporate update. “Our third quarter performance marks a pivotal milestone for Vogenx following our successful public listing in August," said James Green, Chief Executive Officer of Vogenx. “The EMERGE study is now up and running and we have added critical headcount across the Company, positioning us to advance the development of mizagliflozin for both post-bariatric hypoglycemia (PBH) and gastroparesis.” Recent Corporate & Clinical Highlights Clinical Pipeline Update: In October 2026, the Company initiated EMERGE (NCT07760961), a randomized, placebo-controlled, double-blind, parallel-group, Phase 2b study evaluating mizagliflozin 5 mg a…
Open exhibit ↗